State-Level Excess Mortality and Potential Deaths Averted in US Adults During the Delta and Omicron Waves of COVID-19
- PMID: 37620716
- PMCID: PMC10817860
- DOI: 10.1007/s11606-023-08374-2
State-Level Excess Mortality and Potential Deaths Averted in US Adults During the Delta and Omicron Waves of COVID-19
Conflict of interest statement
Dr. Krumholz reported receiving consulting fees from UnitedHealth, Element Science, Aetna, Reality Labs, F-Prime, and Tesseract/4Catalyst; serving as an expert witness for Martin/Baughman law firm, Arnold and Porter law firm, and Siegfried and Jensen law firm; being a cofounder of Hugo Health, a personal health information platform; being a cofounder of Refactor Health, an enterprise health care, artificial intelligence–augmented data management company; receiving contracts from the Centers for Medicare & Medicaid Services through Yale New Haven Hospital to develop and maintain performance measures that are publicly reported; and receiving grants from Johnson & Johnson outside the submitted work. No other disclosures were reported.
Figures
References
-
- Murphy SJ, Samson LW, Sommers BD. COVID-19 Antivirals Utilization: Geographic and Demographic Patterns of Treatment in 2022. Office of the Assistant Secretary for Planning and Evaluation, U.S. Department of Health and Human Services. December 2022.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
